In conclusion, this study shows high concordance rates of FRα expression between primary tumor and corresponding biopsy and metastatic tissue of both breast cancer and NSCLC patients, underscoring applicability of FRα-targeted agents in these patients. This evidence concerns the gene FOLR1 and neoplasm.